M. Padval

发表

The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma

Chenguang Wang, L. Wood, A. Maitra, 2017, PloS one.

A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

Toshio Shimizu, K. Fukuoka, L. Vaickus, 2016, Cancer Chemotherapy and Pharmacology.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantitation of prednisolone and dipyridamole in human plasma and its application in a pharmacokinetic study.

Zhi-yi Zhang, V. Kansra, C. Granvil, 2009, Journal of pharmaceutical and biomedical analysis.

PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma

R. Vij, D. Weaver, A. Azab, 2019, Haematologica.

Liquid chromatographic determination of indapamide in the presence of its degradation products.

H. N. Bhargava, M. Padval, 1993, Journal of pharmaceutical and biomedical analysis.

Combination treatment of mice with CRx-153 (nortriptyline and desloratadine) decreases the severity of experimental autoimmune encephalomyelitis.

S. Miller, J. Podojil, M. Padval, 2011, Cellular immunology.

Pi3k/mtor Dual Inhibitor Vs-5584 Preferentially Targets Cancer Stem Cells Introduction

Qunli Xu, D. Weaver, V. Kolev, 2022 .

PI 3 K / mTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells

Qunli Xu, D. Weaver, V. Kolev, 2014 .

Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship

Andrea I. McClatchey, J. Testa, Qunli Xu, 2014, Science Translational Medicine.

Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer.

Suzanne F. Jones, H. Burris, J. Infante, 2014 .

Biotransformation and in vitro assessment of metabolism-associated drug-drug interaction for CRx-102, a novel combination drug candidate.

Zhi-yi Zhang, V. Kansra, Zhi-Yi Zhang, 2009, Journal of pharmaceutical and biomedical analysis.

Abstract 3327: Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors

D. Bergstrom, M. Murcko, D. Shaw, 2022, Cancer Research.

First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.

M. Borad, A. El-Khoueiry, A. Schram, 2021 .

PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.

Qunli Xu, D. Weaver, V. Kolev, 2015, Cancer Research.

Focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718 target cancer stem cells.

Qunli Xu, V. Kolev, M. Keegan, 2013 .